Nov 12, 2021
Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically significant reduction in plasma galactitol NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.
Aug 12, 2021
NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalents and short-term investments NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.
Jun 28, 2021
NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company has joined
Jun 25, 2021
~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart’s ability to function   People with diabetes or pre-diabetes who have Diabetic Cardiomyopathy are at high risk for developing overt heart failure NEW YORK, June 25,
Displaying 1 - 10 of 21


Print Page
Email Alerts
RSS Feeds
Contact IR